In the fast-paced and highly regulated world of clinical research, pharma and biotech leaders often have numerous questions regarding the processes, technologies, and compliance standards involved. At Lambda Therapeutic Research,…
Regulations, Notices & Guidance June 10, 2024: The FDA announced the "Emerging Drug Safety Technology Meetings; Program Announcement." The Center for Drug Evaluation and Research (CDER) introduced the Emerging Drug…
The FDA recently unveiled the draft guidance for the industry titled, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies.” This draft guidance serves as a framework for maintaining the highest standards of data integrity in clinical and bioanalytical domains, crucial for supporting investigational new drug applications, new drug applications, and abbreviated new drug applications.
The FDA recently unveiled the draft guidance for the industry titled, “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies.” This draft guidance serves as a framework for maintaining the highest standards of data integrity in clinical and bioanalytical domains, crucial for supporting investigational new drug applications, new drug applications, and abbreviated new drug applications.
Navigating the world of clinical research can be complex, especially with the array of specialized terminology. To help, we've compiled a clinical research glossary of some of the most commonly…
